Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Antisense oligonucleotide-based therapeutics for cancer

Oncogene volume 22, pages 9087–9096 (2003)Cite this article

Abstract

There has been steady progress in antisense technology over the past 14 years. We now have a far better appreciation of the attributes and limitations of the technology. Antisense oligonucleotides have been used to selectively inhibit thousands of genes in mammalian cells, hundreds, if not thousands, of genes in rodents and other species and multiple genes in humans. There are over 20 antisense drugs currently in clinical trials, several of which are showing promising results. Like any other class of drugs in development, there will continue to be successes and failures in the clinic. Despite some disappointments with the technology, it appears to be a valid platform for both drug discovery and as an experimental tool for functionalizing genes. Advances in the medicinal chemistry and formulation of antisense oligonucleotides will further enhance their therapeutic and commercial potential.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  • Agrawal S, Kandimalla ER, Yu D, Ball R, Lombardi G, Lucas T, Dexter DL, Hollister BA and Chen SF . (2002). Int. J. Oncol., 21, 65–72.

  • Agrawal S, Temsamani J and Tang JY . (1991). Proc. Natl. Acad. Sci. USA, 88, 7595–7599.

  • Agrawal S, Zhang X, Lu Z, Zhao H, Tamburin JM, Yan J, Cai H, Diasio RB, Habus I, Jiang Z, Iyer RP, Yu D and Zhang R . (1995). Biochem. Pharm., 50, 571–576.

  • Altieri DC . (2003). Nat. Rev. Cancer, 3, 46–54.

  • Ashrafi K, Chang FY, Watts JL, Fraser AG, Kamath RS, Ahringer J and Ruvkun G. . (2003). Nature, 421, 268–272.

  • Baker BF, Lot SS, Condon TP, Cheng-Flournoy S, Lesnik EA, Sasmor HM and Bennett CF . (1997) 272, 11994–12000.

  • Banerjee D . (2001). Curr. Opin. Investig. Drugs, 2, 574–580.

  • Braasch DA and Corey DR . (2001). Chem. Biol., 8, 1–7.

  • Breaker RR and Joyce GF . (1994). Chem. Biol., 1, 223–299.

  • Bulavin DV, Higashimoto Y, Popoff IJ, Gaarde WA, Basrur V, Potapovas O, Appella E and Fornace Jr. AJ . (2001). Nature, 411, 102–107.

  • Butler M, Crooke R, Graham M, Lougheed M, Murray S, Witchell DR, Steinbrecher U and Bennett CF . (2000). J. Pharm. Exp. Ther., 292, 489–496.

  • Butler M, Stecker K and Bennett CF . (1997). Lab. Invest., 77, 379–388.

  • Caplen NJ, Parrish S, Imani F, Fire A and Morgan RA . (2001). Proc. Natl. Acad. Sci. USA, 98, 9742–9747.

  • Cech TR and Uhlenbeck OC . (1994). Nature, 372, 39–40.

  • Chen J, Wu W, Tahir SK, Kroeger PE, Rosenberg SH, Cowsert LM, Bennett F, Krajewski S, Krajewski M, Welsh K, Reed JC and Ng SC . (2000). Neoplasia, 2, 235–241.

  • Cook PD . (2001). Antisense Drug Technology: Principles, Strategies, and Applications, Crooke ST (ed). Marcel Dekker: New York, pp. 29–58.

    Google Scholar 

  • Cossum PA, Sasmor H, Dellinger D, Truong L, Cummins L, Owens SR, Markham PM, Shea JP and Crooke S . (1993). J. Pharmacol. Exp. Ther., 267, 1181–1190.

  • Crooke ST . (1999). Biochim. Biophys. Acta, 1489, 30–42.

  • De Backer MD, Nelissen B, Logghe M, Viaene J, Loonen I, Vandoninck S, de Hoogt R, Dewaele S, Simons FA, Verhasselt P, Vanhoof G, Contreras R and Luyten WHML . (2001). Nat. Biotech., 19, 235–241.

  • Dean NM, McKay R, Condon TP and Bennett CF . (1994). J. Biol. Chem., 269, 16416–16424.

  • Dominski Z and Kole R . (1993). Proc. Natl. Acad. Sci. USA, 90, 8673–8677.

  • Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K and Tuschl T . (2001). Nature, 411, 494–498.

  • Fennell DA, Corbo MV, Dean NM, Monia BP and Cotter FE . (2001). Br. J. Haemat., 112, 706–712.

  • Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE and Mello CC . (1998). Nature, 391, 806–811.

  • Flanagan WM, Wolf JJ, Olson P, Grant D, Lin KY, Wagner RW and Matteucci MD . (1999). Proc. Natl. Acad. Sci. USA, 96, 3513–3518.

  • Freier SM and Altmann K-H . (1997). Nucleic Acids Res., 25, 4429–4443.

  • Galbraith WM, Hobson WC, Giclas PC, Schechter PJ and Agrawal S . (1994). Antisense Res. Dev., 4, 201–206.

  • Geary RS, Leeds JM, Henry SP, Monteith DK and Levin AA . (1997). Anti-Cancer Drug Design, 12, 383–393.

  • Geary RS, Watanabe TA, Truong L, Freier S, Lesnik EA, Sioufi NB, Sasmor H, Manoharan M and Levin AA . (2001). J. Pharmacol. Exp. Ther., 296, 890–897.

  • Gottschalk AR, Basila D, Wong M, Dean NM, Brandts CH, Stokoe D and Haas-Kogan DA . (2001). Cancer Res., 61, 2105–2111.

  • Graham MJ, Crooke ST, Monteith DK, Cooper SR, Lemonidis KM, Stecker KK, Martin MJ and Crooke RM . (1998). J. Pharmacol. Exp. Ther., 286, 447–458.

  • Harborth J, Elbashir SM, Bechert K, Tuschl T and Weber K . (2001). J. Cell Sci., 114, 4557–4565.

  • Henry SP, Giclas PC, Leeds J, Pangburn M, Auletta C, Levin AA and Kornbrust DJ . (1997a). J. Pharmacol. Exp. Ther., 281, 810–816.

  • Henry SP, Novotny W, Leeds J, Auletta C and Kornbrust DJ . (1997b). Antisense Nucleic Acid Drug Dev., 7, 503–510.

  • Henry S, Stecker K, Brooks D, Monteith D, Conklin B and Bennett CF . (2000). J. Pharm. Exp. Ther., 292, 468–479.

  • Hu Y, Cherton-Horvat G, Dragowska V, Baird S, Korneluk RG, Durkin JP, Mayer LD and LaCasse EC . (2003). Clin. Cancer Res., 9, 2826–2836.

  • Kamath RS, Fraser AG, Dong Y, Poulin G, Durbin R, Gotta M, Kanapin A, Le Bot N, Moreno S, Sohrmann M, Welchman DP, Zipperien P and Ahringer J . (2003). Nature, 421, 231–237.

  • Klasa RJ, Gillum AM, Klem RE and Frankel SR . (2002). Antisense Nucleic Acid Drug Dev., 12, 193–213.

  • Krieg AM, Yi A-K, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA and Klinman DM . (1995). Nature, 374, 546–549.

  • Kuss BJ, Corbo M, Lau WM, Fennell DA, Dean NM and Cotter FE . (2002). Int. J. Cancer, 98, 128–133.

  • Larsen HJ, Bentin T and Nielsen PE . (1999). Biochim. Biophys. Acta, 1489, 159–166.

  • Leaman DW, Longano FJ, Okicki JR, Soike KF, Torrence PF, Silverman RH and Cramer H . (2002). Virology, 292, 70–77.

  • Lebedeva I and Stein CA . (2001). Ann. Rev. Pharmacol. Toxicol., 41, 403–419.

  • Lee Y, Vassilakos A, Feng N, Lam V, Xie H, Wang M, Jin H, Xiong K, Liu C, Wright J and Young A . (2003). Cancer Res., 63, 2802–2811.

  • Levin AA, Henry SP, Monteith D and Templin MV . (2001). Antisense Drug Technology: Principles, Strategies, and Applications, Crooke ST (ed). Marcel Dekker: New York, pp. 201–267.

    Google Scholar 

  • Li F, Ackermann EJ, Bennett CF, Rothermel AL, Plescia J, Tognin S, Villa A, Marchisio PC and Altieri DC . (1999). Nat. Cell Biol., 1, 461–466.

  • Lima WF, Wu H and Crooke ST . (2001). Methods Enzymol., 341, 430–440.

  • Mani S, Rudin CM, Kunkel K, Holmlund JT, Geary RS, Kindler HL, Dorr FA and Ratain MJ . (2002). Clin. Cancer Res., 8, 1042–1048.

  • Martinez J, Patkaniowska A, Urlaub H, Luhrmann R and Tuschl T . (2002). Cell, 110, 563–574.

  • McKay RA, Miraglia LJ, Cummins LL, Owens SR, Sasmor H and Dean NM . (1999). J. Biol. Chem., 274, 1715–1722.

  • McMahon BM, Mays D, Lipsky J, Stewart JA, Fauq A and Richelson E . (2002). Antisense Nucleic Acid Drug Dev., 12, 65–73.

  • McManus MT and Sharp PA . (2002). Nat. Rev. Genet., 3, 737–747.

  • Mercatante DR, Mohler JL and Kole R . (2002). J. Biol.Chem., 277, 49374–49832.

  • Miyake H, Hara I, Kamidono S and Gleave ME . (2001). Clin Cancer Res., 7, 4245–4252.

  • Mohammad R, Abubakr Y, Dan M, Aboukameel A, Chow C, Mohamed A, Hamdy N and Al-Katib A . (2002). Clin. Cancer Res., 8, 1277–1283.

  • Monia BP, Lesnik EA, Gonzalez C, Lima WF, McGee D, Guinosso CJ, Kawasaki AM, Cook PD and Freier SM . (1993). J. Biol. Chem., 268, 14514–14522.

  • Nemuanaitis J, Holmlund JT, Kraynak M, Richards D, Bruce J, Ognoskie N, Kwoh TJ, Geary RS, Dorr A, Von Hoff D and Eckhardt SG . (1999). J. Clin. Oncol., 17, 3586–3595.

  • Nylandsted J, Wick W, Hirt UA, Brand K, Rohde M, Leist M, Weller M and Jaattela M . (2002). Cancer Res., 62, 7139–7142.

  • Pedersen IM, Kitada S, Looni LM, Karras J, Tsukada T, Kipps TJ, Choi YS, Bennett F and Reed JC . (2002). Blood, 100, 1795–1801.

  • Rankin R, Pontarollo R, Ioannou X, Krieg AM, Hecker R, Babiuk LA and vanDrunen Littel-va den Hurk S . (2001). Antisense Nucleic Acid Drug Dev., 11, 333–340.

  • Sazani P, Gemignani F, Kang SH, Maier MA, Manoharan M, Persmark M, Bortner D and Kole R . (2002). Nat. Biotechnol., 20, 1228–1233.

  • Sazani P, Kang SH, Maier MA, Wei C, Dillman J, Summerton J, Manoharan M and Kole R . (2001). Nucleic Acids Res., 29, 3965–3974.

  • Sewell LK, Geary RS, Baker BF, Glover JM, Mant TGK, Yu RZ, Tami JA and Dorr FA. . (2002). J. Pharm. Exp. Ther., 303, 1334–1343.

  • Sheehan JP and Phan TM . (2001). Biochemistry, 40, 4980–4989.

  • Shen L, Siwkowski A, Wancewicz EV, Lesnik EA, Butler M, Witchell D, Vasquez G, Ross B, Acevedo O, Inamati G, Sasmor H, Manoharan M and Monia BP . (2003). Antisense Nucleic Acid Drug Dev., 13, 129–142.

  • Song E, Lee S-K, Wang J, Ince N, Ouyang N, Min J, Chen J, Shankar P and Lieberman J . (2003). Nat. Med., 9, 347–351.

  • Stehelin D, Varmus HE, Bishop JM and Vogt PK . (1976). Nature, 260, 70–73.

  • Summerton J . (1999). Biochim. Biophys. Acta, 1489, 141–158.

  • Tamm I, Dorken B and Hartmann G . (2001). Lancet, 358, 489–497.

  • Taylor JK and Dean NM . (1999). Curr. Opin. Drug Disc. Dev., 2, 147–151.

  • Taylor J, Zhang Q, Monia B, Marcusson E and Dean N . (1999a). Oncogene, 18, 4495–4504.

  • Taylor J, Zhang Q, Wyatt J and Dean N . (1999b). Nat. Biotech., 17, 1097–1100.

  • Thallinger C, Wolschek MF, Wachek V, Maierhofer H, Gunsberg P, Polterauer P, Pehamberger H, Monia BP, Selzer E, Wolff K and Jansen B . (2003). J. Invest. Dermatol., 120, 1081–1086.

  • Torrence PF, Maitra RK, Lesiak K, Khamnei S, Zhou A and Silverman RH . (1993). Proc. Natl. Acad. Sci. USA, 90, 1300–1304.

  • Tortora G, Caputo R, Damiano V, Bianco R, Fontanini G, Cuccato S, De Placido S, Bianco AR and Ciardiello F . (2001). Clin. Cancer Res., 7, 2537–2544.

  • Urban G, Golden T, Aragon IV, Scammell JG, Dean NM and Honkanen RE . (2001). J. Biol. Chem., 276, 27638–27646.

  • Verma UN, Surabhi RM, Schmaltieg A, Becerra C and Gaynor RB . (2003). Clin. Cancer Res., 9, 1291–1300.

  • Vickers TA, Wyatt JR, Burckin T, Bennett CF and Freier SM . (2001). Nucleic Acids Res., 29, 1293–1299.

  • Vickers TA, Koo S, Bennett CF, Crooke ST, Dean NM and Baker B . (2003). J. Biol.Chem., 278, 7108–7118.

  • Wagner RW, Matteucci MD, Lewis JG, Gutierrez AJ, Moulds C and Froehler BC . (1993). Science, 260, 1510–1513.

  • Wang H, Hang J, Shi Z, Li M, Yu D, Kandimalla ER, Agrawal S and Zhang R . (2002). Int. J. Oncol., 21, 73–80.

  • Weng DE and Usman N . (2001). Curr. Oncol. Rep., 3, 141–146.

  • Wengel J . (1999). Accounts Chem. Res., 32, 301–308.

  • Wu H, Lima WF and Crooke ST . (1999). J. Biol. Chem., 274, 28270–28278.

  • Wu H, Macleod AR, Lima WF and Crooke ST . (1998). J. Biol. Chem., 273, 2532–2542.

  • Yu RZ, Zhang H, Geary RS, Graham M, Masarjian L, Lemonidis K, Crooke R, Dean NM and Levin AA . (2001). J. Pharmacol. Exp. Ther., 296, 388–395.

  • Zamore PD . (2002). Science, 296, 1265–1269.

  • Zamore PD, Tuschl T, Sharp PA and Bartel DP . (2000). Cell, 101, 25–33.

  • Zellweger T, Miyake H, Cooper S, Chi K, Conklin BS, Monia BP and Gleave ME . (2001). J. Pharmacol. Exp. Ther., 298, 934–940.

  • Zender L, Hutker S, Liedtke C, Tillmann HL, Zender S, Mundt B, Waltermathe M, Gosling T, Flemming P, Malek NP, Trautwein C, Manns MP, Kuhnel F and Kubicka S . (2003). Proc. Natl. Acad. Sci. USA, 100, 7797–7802.

  • Zhang H, Cook J, Nickel J, Yu R, Stecker K, Myers K and Dean NM . (2000). Nat. Biotech., 18, 862–867.

  • Zhang H, Taylor J, Luther D, Johnston J, Murray S, Wyatt JR, Watt AT, Koo S, York-Defalco C, Stecker K and Dean NM . (2003). J. Pharmacol. Exp. Ther., 307, 24–33.

  • Zhang R, Lu Z, Zhao H, Zhang X, Diasio RB, Habus I, Jiang Z, Iyer RP, Yu D and Agrawal S . (1995). Biochem. Pharm., 50, 545–556.

  • Zhao Q, Temsamani J, Iadarola PL, Jiang Z and Agrawal S . (1995). Biochem. Pharmacol., 51, 173–182.

Download references

Acknowledgements

The authors thank Kathy McGraw for help in preparing Figures 1 and 2.

Author information

Authors and Affiliations

  1. ISIS Pharmaceuticals, 2282 Faraday Ave., Carlsbad, 92008, CA, USA

    Nicholas M Dean & C Frank Bennett

Authors
  1. Nicholas M Dean
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C Frank Bennett
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C Frank Bennett.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dean, N., Bennett, C. Antisense oligonucleotide-based therapeutics for cancer. Oncogene 22, 9087–9096 (2003). https://doi.org/10.1038/sj.onc.1207231

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1207231

Keywords

This article is cited by

Search

Advanced search

Quick links